Influenza-the need to stay ahead of the virus

Eurosurveillance

Volumn 20, Issue 5, 2015, Pages 1-4

  van der Werf, S ^a,b   Levy Bruhl D ^c  

^a Sorbonne Paris Cité   (France)

^b INSTITUT PASTEUR   (France)

^c INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ANTIGEN SPECIFICITY; ANTIGENICITY; CROSS PROTECTION; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; EUROPE; GENE SEQUENCE; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; PUBLIC-PRIVATE PARTNERSHIP; RISK ASSESSMENT; SEROLOGY; WORLD HEALTH ORGANIZATION; FLU LIKE SYNDROME; HEALTH PRACTITIONER; IMMUNOGENICITY; NONHUMAN; PROPHYLAXIS; PUBLIC HEALTH; VACCINATION REACTION; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; SENTINEL SURVEILLANCE; VIROLOGY;

HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; SENTINEL SURVEILLANCE;

EID: 84922775989     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, et al., on behalf of the WHO European Region and the European Influenza Surveillance Network. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill. 2015;20(4):21023.
2. Haveri A, Ikonen N, Julkunen I, Kantele A, Anttila VJ, Ruotsalainen E, et al. Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine. Euro Surveill. 2015;20(5):pii=21028.
3. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022.
4. McNeil SA, Andrew MK, Ye L, Haguinet F, Hatchette TF, ElSherif M, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill. 2015;20(5):pii=21024
5. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015;20(5):pii=21025
6. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al.; Centers for Disease Prevention and Control. Early estimates of seasonal influenza vaccine effectiveness United States, january 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PMID:25590680
7. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed 5 Feb 2015]. Available from: http://www.who.int/ influenza/vaccines/virus/recommendations/en/
8. Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, et al.; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013-2014. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine. 2014;32(37):4713-25. http://dx.doi.org/10.1016/j.vaccine.2014.02.014 PMID:24582632
9. Ampofo WK, Al Busaidy S, Cox NJ, Giovanni M, Hay A, Huang S, et al. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine. 2013;31(32):3209-21. doi: 10.1016/j.vaccine.2013.05.049
10. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. http://dx.doi.org/10.1126/science.1244730 PMID:24264991
11. Koel BF, Mögling R, Chutinimitkul S, Fraaij PL, Burke DF, van der Vliet S, et al. Identification of amino acid substitutions supporting antigenic change of A(H1N1)pdm09 viruses. J Virol. 2015 Jan 21. pii: JVI.02962-14. [Epub ahead of print]
12. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153.
13. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013Jun 25;11:153. doi: 10.1186/1741-7015-11-153. Review.PMID: 23800265.
14. Neuzil KM. How Can We Solve the Enigma of Influenza Vaccine- Induced Protection? J Infect Dis. 2014 Nov 21. pii: jiu651. [Epub ahead of print]. PMID: 2541681.
15. Lafond KE, Tam JS, Bresee JS, Widdowson MA. International meeting on influenza vaccine effectiveness, 3-4 December 2012, Geneva, Switzerland. Vaccine. 2014;32(49):6591-5. PMID:25446822
16. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010;28(46):7381-8. http://dx.doi.org/10.1016/j.vaccine.2010.09.010 PMID:20851086
17. Valenciano M, Ciancio B; I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill. 2012;17(39):20281. PMID:23041022
18. World Health Organization (WHO). Questions and Answers.Recommended composition of influenza virus vaccines for use in the northern hemisphere 2014-15 influenza seasonal and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO. [Accessed 4 Feb 2015]. Available4 from: http://www.who.int/influenza/vaccines/virus/recommendations/201402_qanda_recommendation.pdf?ua=1
19. European Medicines Agency (EMA). Explanatory note on the withdrawal of the Note for guidance on harmonisation of requirements for influenza Vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines. 23 Jan 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500161022.pdf)
20. Innovative Medicines Initiative (IMI). Key organisations unite to improve benefits and risk assessments of vaccines. Brussels:IMI. 26 Nov 2013. Available from: http://www.imi.europa.eu/ content/press-release-advance
21. European Centre for Disease Prevention and Control (ECDC). Risk assessment. Seasonal influenza in the EU/EEA countries,2014-2015. Stockholm: ECDC; Jan 2015. Available from: http://www.ecdc.europa.eu/en/publications/Publications/seasonalinfluenza-risk-assessment.pdf
22. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013 Dec 5;31(50):6030-3. doi: 10.1016/j.vaccine.2013.09.063
23. Pica N, Palese P. Toward a universal influenza virus vaccine:prospects and challenges. Annu Rev Med. 2013;64:189-202. doi: 10.1146/annurev-med-120611-145115. Review. PMID:23327522.